# The partners will deploy the highly agile ChAdOx1 viral- vector platform developed by the University of Oxford.

*biotech · news · 2026-05-26 · Livemint*

## Key points

- SII will use Oxford’s ChAdOx1 platform to produce Bundibugyo Ebola vaccine doses within 20-30 days.
- There are currently no licensed vaccines or therapies for the Bundibugyo Ebola virus.
- WHO has declared the Bundibugyo Ebola outbreak a Public Health Emergency of International Concern.
- India has introduced stringent entry screening, including thermal scans and mandatory forms, for high-risk travelers.

**Companies:** Serum Institute of India, University of Oxford
**Countries:** India, Democratic Republic of the Congo, Uganda, South Sudan

[Read the full story on Livemint](https://www.livemint.com/news/india/serum-institute-of-india-oxford-university-cepi-ebola-bundibugyo-strain-vaccine-11779800551191.html)

---

Canonical: https://newsio.io/n/bd8f5520-c0ec-4e67-8b3c-ec0f8eb330b9/the-partners-will-deploy-the-highly-agile-chadox1-viral-vector-platform-develope
Summarized by Newsio from Livemint. https://newsio.io/how-it-works